Effects of an oral contraceptive containing estradiol valerate and dienogest on circulating androgen levels and acne in young patients with PCOS: an observational preliminary study
article
OA: closed
CC0
⤵ 5 in-corpus citations
Abstract
This study shows the effect of a 1 year treatment with an estradiol valerate/dienogest pill in 36 women suffering from polycystic ovaries and mild or moderate acne. At beginning of the study, 24 patients (66.7%) had grade 1-2 (mild) acne and 12 patients (33.3%) had grade 3 (moderate) acne. After 12 cycles of therapy, we found an improvement of acne in 19 (52.8%) patients and a worsening of acne in 3 (8.4%) patients. The percentage of patients recovered was statistically significant (p < 0.01). SHBG levels were significantly higher after 6 and 12 months of therapy (p < 0.001), while total testosterone levels were lower in all patients at 6 and 12 months although this trend did not reach statistical significance. In conclusion, the present study suggests that the E2V/DNG pill could exert a positive influence on acne and hyperandrogenism. Since this is an observational study on a very limited population number, additional randomized controlled studies on larger populations are needed also to determine the effects of this contraceptive over longer periods of use.
My notes (saved in your browser only)
Citation neighborhood
Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.
References (26)
- Efficacy of a combined oral contraceptive containing 0.030 mg ethinylestradiol/2 mg dienogest for the treatment of papulopustular acne in comparison with placebo and 0.035 mg ethinylestradiol/2 mg cyproterone acetate via openalex
- Pharmacological profile of progestins via openalex
- Preliminary Study on the Effect of Four-phasic Estradiol Valerate and Dienogest (E2V/DNG) Oral Contraceptive on the Quality of Sexual Life via openalex
- Reprint of Pharmacological profile of progestins via openalex
- Review of the safety, efficacy and patient acceptability of the combined dienogest/estradiol valerate contraceptive pill via openalex
- The use of newer progestins for contraception via openalex
- doi:10.1080/1362518042000221508 via openalex
- doi:10.1001/archderm.134.4.454 via openalex
- doi:10.1055/s-2007-1021407 via openalex
- W76793071 via openalex
- W2402629557 via openalex
- doi:10.1016/0010-7824(95)00098-u via openalex
- doi:10.1016/0010-7824(90)90034-s via openalex
- doi:10.1016/0002-9378(87)90238-9 via openalex
- doi:10.1056/nejm199509283331307 via openalex
- doi:10.1210/er.2002-0015 via openalex
- doi:10.1016/s0015-0282(16)53212-9 via openalex
- doi:10.1016/j.fertnstert.2003.10.004 via openalex
- doi:10.1136/adc.77.1.89 via openalex
- doi:10.3109/13625180903585431 via openalex
- doi:10.1111/j.1365-2265.1985.tb01061.x via openalex
- doi:10.1016/j.maturitas.2012.01.018 via openalex
- doi:10.1016/s0029-7844(02)02725-4 via openalex
- doi:10.1210/jc.2007-2437 via openalex
- doi:10.1016/j.rigp.2004.05.001 via openalex
- doi:10.1111/j.1600-0846.2011.00542.x via openalex
Cited by (5)
- Estradiol Valerate vs Ethinylestradiol in Combined Oral Contraceptives: Effects on the Pituitary-Ovarian Axis 2022
- A prospective randomized trial comparing two different oral contraceptive containing dienogest or drospirenone for the treatment of hirsutism in policystic ovarian syndrome 2020
- Overview of the therapeutic possibilities of combined oral contraceptive containing estradiol valerate and dienogest 2019
- Use of oral contraceptives for management of acne vulgaris and hirsutism in women of reproductive and late reproductive age 2018
- Noncontraceptive benefits of the estradiol valerate/dienogest combined oral contraceptive: a review of the literature 2014
Source provenance
- openalex
- last seen: 2026-05-11T07:08:39.058960+00:00
License: CC0
· commercial use OK